- Trials with a EudraCT protocol (85)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
85 result(s) found for: Stool sample.
Displaying page 4 of 5.
EudraCT Number: 2019-001015-23 | Sponsor Protocol Number: APHP180668 | Start Date*: 2020-05-13 |
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | ||
Full Title: Double blind, multicentric, randomized, placebo-controlled trial, evaluating the efficacy of 24-month of bezafibrate in primary sclerosing cholangitis with persistent cholestasis despite ursodeoxyc... | ||
Medical condition: Adult patients with primary sclerosing cholangitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000252-34 | Sponsor Protocol Number: LCD-CDAD-10-07 | Start Date*: 2012-12-06 | |||||||||||
Sponsor Name:Cubist Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients with Clostridium Difficile Associated Diarrhea | |||||||||||||
Medical condition: Clostridium difficile Associated Diarrhea | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) ES (Completed) AT (Completed) GB (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001684-22 | Sponsor Protocol Number: UAM4 | Start Date*: 2018-10-11 | |||||||||||
Sponsor Name:University of Antwerp | |||||||||||||
Full Title: A Phase 2, partial blind, randomized, placebo-controlled, multicenter study to evaluate the safety and immunogenicity of two novel live attenuated serotype 2 oral poliovirus vaccines candidates, in... | |||||||||||||
Medical condition: Poliomyelitis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000381-35 | Sponsor Protocol Number: OVG 2011/02 | Start Date*: 2011-09-26 | ||||||||||||||||
Sponsor Name:University of Oxford | ||||||||||||||||||
Full Title: Understanding typhoid disease after vaccination: a single centre, randomised, double-blind, placebo-controlled study to evaluate M01ZH09 in a healthy adult challenge model, using Ty21a vaccine as a... | ||||||||||||||||||
Medical condition: Active immunisation for the prevention of typhoid infection in healthy adults. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-002097-51 | Sponsor Protocol Number: FLT190-01 | Start Date*: 2020-02-12 | |||||||||||
Sponsor Name:Freeline Therapeutics Ltd | |||||||||||||
Full Title: A Phase 1/2, Baseline-controlled, Non-randomized, Open-label, Single-ascending Dose Study of a Novel Adeno-associated Viral Vector (FLT190) in Patients With Fabry disease | |||||||||||||
Medical condition: Fabry disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001085-37 | Sponsor Protocol Number: IB2021-05 | Start Date*: 2021-10-14 | ||||||||||||||||
Sponsor Name:Institut Bergonié | ||||||||||||||||||
Full Title: Randomized phase II study of neoadjuvant chemotherapy plus retifanlimab (INCMGA00012) plus in patients with selected retroperitoneal sarcomas. | ||||||||||||||||||
Medical condition: retroperitoneal sarcomas | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003653-26 | Sponsor Protocol Number: OVG2011/07 | Start Date*: 2011-12-08 | |||||||||||
Sponsor Name:Clinical Trials and Research Governance | |||||||||||||
Full Title: A phase II, single-centre, randomised, single-blind, study to evaluate Vi-CRM197 against historical unvaccinated controls in a healthy adult challenge model, with a Vi-PS vaccine control arm. | |||||||||||||
Medical condition: Prophylaxis for Salmonella enterica serovar Typhi (S. Typhi) disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000047-31 | Sponsor Protocol Number: AMT-101-202 | Start Date*: 2020-08-03 | |||||||||||
Sponsor Name:Applied Molecular Transport Inc. | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multicenter, Phase 2a Study of the Efficacy and Safety of Oral AMT-101 in Subjects with Moderate to Severe Ulcerative Colitis | |||||||||||||
Medical condition: Ulcerative Colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) HU (Completed) DE (Completed) BG (Completed) IT (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-002508-13 | Sponsor Protocol Number: PADHIF00704 | Start Date*: 2005-04-13 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-Selection Study of Ad2/Hypoxia Inducible Factor HIF-1alfa/VP16 in Patients with Intermittent Claudication. | |||||||||||||
Medical condition: Peripheral Arterial Disease (PAD): Intermittent Claudication (IC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004588-30 | Sponsor Protocol Number: TED-C13-003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:NPS Pharmaceuticals, Inc. | |||||||||||||
Full Title: A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year through 17 Years, with Short Bowel Syndrome who are Dependent on Parenteral Support | |||||||||||||
Medical condition: Short Bowel Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000324-17 | Sponsor Protocol Number: GA18/118305 | Start Date*: 2019-08-02 | ||||||||||||||||
Sponsor Name:University of Leeds | ||||||||||||||||||
Full Title: Amitriptyline at Low-dose and Titrated for Irritable Bowel Syndrome as Second-line Treatment (The ATLANTIS study): A Double-blind Placebo-controlled Trial | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome (IBS) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001989-38 | Sponsor Protocol Number: IMCRELA | Start Date*: 2021-07-08 | |||||||||||
Sponsor Name:Facultad de medicina y ciencias de la salud de la Universidad Católica de Valencia | |||||||||||||
Full Title: IMPACT OF THE COMBINED TREATMENT OF THE LIPOSOMATED POLYPHENOLS CÚRCULA AND RESVERATROL® WITH DUTASTERIDE, IN THE CLINICAL IMPROVEMENT OF PATIENTS WITH ALS TREATED WITH RILUZOLE | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004696-41 | Sponsor Protocol Number: 2020/3130 | Start Date*: 2021-11-04 | ||||||||||||||||
Sponsor Name:Gustave Roussy | ||||||||||||||||||
Full Title: Randomized Preoperative Breast Immune Selection (BIS) Program in patients with early breast cancer | ||||||||||||||||||
Medical condition: Newly diagnosed, non-metastatic early triple negative or HER2+ breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001648-24 | Sponsor Protocol Number: MedOPP321_ABIGAIL | Start Date*: 2021-06-23 | |||||||||||
Sponsor Name:MEDICA SCIENTIA INNOVATION RESEARCH S.L. | |||||||||||||
Full Title: randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as f... | |||||||||||||
Medical condition: Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease crite... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) PT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001214-24 | Sponsor Protocol Number: PTI-428-01 | Start Date*: 2017-07-27 | |||||||||||
Sponsor Name:Proteostasis Therapeutics | |||||||||||||
Full Title: A Phase I/II Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects with Cystic Fibrosis | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004210-35 | Sponsor Protocol Number: ABC-HCC | Start Date*: 2021-02-25 | |||||||||||
Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH | |||||||||||||
Full Title: The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage Hepatocellular carcin... | |||||||||||||
Medical condition: intermediate-stage hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000667-24 | Sponsor Protocol Number: ST-920-201 | Start Date*: 2019-11-12 | |||||||||||
Sponsor Name:Sangamo Therapeutics, Inc. | |||||||||||||
Full Title: A Phase I/II, Multicenter, Open-Label, SingleDose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a rAAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects with Fabry Dise... | |||||||||||||
Medical condition: Fabry Disease (X-linked lysosomal storage disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002771-25 | Sponsor Protocol Number: NSABP_B-59/GBG96 | Start Date*: 2018-04-03 | |||||||||||
Sponsor Name:NSABP Foundation Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of At... | |||||||||||||
Medical condition: Patients with early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002678-31 | Sponsor Protocol Number: CA184-007 | Start Date*: 2006-03-20 | |||||||||||
Sponsor Name:BRISTOL-M.SQUIBB | |||||||||||||
Full Title: Randomized, double-blind, placebo controlled phase II study comparing the safety of MDX-010 BMS-734016 administered with or without prophylactic oral budesonide Entocort EC in patients with unr... | |||||||||||||
Medical condition: Melanoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003931-27 | Sponsor Protocol Number: GI2118 | Start Date*: 2021-10-20 | ||||||||||||||||
Sponsor Name:Department of Oncology, Herlev & Gentofte Hospital | ||||||||||||||||||
Full Title: Nivolumab, ipilimumab and radiation in combination with influenza vaccine in patients with pancreatic cancer. | ||||||||||||||||||
Medical condition: Metastatic pancreatic cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
